Medical News
Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period…
Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the control of bleeding in patients with congenital hemophilia A and inhibitors but also help to prevent such…
Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
The aim of the review article by Brazilian authors was to summarize the efficacy and safety of metamizole in the treatment of acute primary headaches, such as migraine, episodic tension-type headache…
Memantine Eases Daily Life for Patients and Caregivers
What is the efficacy and safety of memantine in patients with Alzheimer's disease in routine practice in the Czech Republic? And to what extent can it ease the burden on caregivers of these patients?
Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the treatment with pegylated recombinant factor VIII (rVIII) in real clinical practice. This is the most…
Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.
Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Authors of a recently published study attempted to determine the value of minimum and optimal levels of coagulation factors in patients with severe hemophilia who engage in physical activities.
Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Turkish authors in their study focused on the use of metamizole in addressing vasospasm in microsurgery. Using an animal model, they sought to answer the question of how this drug compares to…
Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of…
Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
A recent survey among German-speaking physicians evaluated the use of non-opioid analgesics in perioperative care in children under 14 years. It focused on the use of metamizole and the monitoring of…
Popular this week
- Probiotics in antibiotic treatment – an overview of effectiveness, risks, and recommended practices
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- A kidney for sale – I need the money
- Analgesic-muscle relaxant infusion in back pain therapy – technological and clinical aspects
- The TEST According to Véle or the VÉLE-TEST